Nurix investors back directors, auditor and pay
Nurix Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held online.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held online. A quorum was reached, with 83,747,013 shares of common stock present, representing approximately 80.98% of the voting power entitled to vote as of March 20, 2026.
Stockholders elected three Class III directors—Arthur T. Sands, M.D., Ph.D., Roger Dansey, M.D., and Paul M. Silva—to three-year terms ending at the 2029 annual meeting. Each will serve until a successor is elected and qualified or earlier resignation or removal.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending November 30, 2026. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares represented at meeting: 83,747,013 shares
Quorum voting power: 80.98%
Auditor ratification votes for: 83,555,977 votes
+5 more
8 metrics
Shares represented at meeting
83,747,013 shares
Common stock present at 2026 annual meeting; 80.98% voting power
Quorum voting power
80.98%
Voting power of shares entitled to vote at 2026 meeting
Auditor ratification votes for
83,555,977 votes
Support for PricewaterhouseCoopers LLP as 2026 auditor
Auditor votes against
166,391 votes
Opposition to ratifying PricewaterhouseCoopers LLP
Say-on-pay votes for
72,458,920 votes
Support for named executive officer compensation
Say-on-pay votes against
6,895,394 votes
Votes against executive compensation proposal
Votes for Roger Dansey
79,607,489 votes
For-election votes for Class III director nominee
Votes for Arthur T. Sands
63,592,948 votes
For-election votes for Class III director nominee
Key Terms
broker non-votes, independent registered public accounting firm, non-binding advisory basis, quorum, +1 more
5 terms
broker non-votes financial
"Nominee | Votes For | Votes Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding advisory basis financial
"To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
quorum financial
"constituted a quorum for the transaction of business"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
named executive officers financial
"the compensation of the Company’s named executive officers as disclosed in the Proxy Statement"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Nurix Therapeutics (NRIX) stockholders vote on at the 2026 annual meeting?
Stockholders voted on three items: electing three Class III directors, ratifying PricewaterhouseCoopers LLP as auditor for fiscal 2026, and approving executive compensation on a non-binding advisory basis, all as described in the March 27, 2026 proxy statement.
Was there a quorum at Nurix Therapeutics’ 2026 annual stockholder meeting?
Yes, there was a quorum. 83,747,013 shares of common stock were present in person or by proxy, representing approximately 80.98% of the voting power entitled to vote as of March 20, 2026.
Which directors were elected at Nurix Therapeutics’ 2026 annual meeting and for how long?
Arthur T. Sands, M.D., Ph.D., Roger Dansey, M.D., and Paul M. Silva were elected as Class III directors to three-year terms, expiring at the 2029 annual stockholder meeting, serving until a successor is elected and qualified or earlier resignation or removal.
Did Nurix Therapeutics stockholders ratify the 2026 independent auditor?
Yes. Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending November 30, 2026, with 83,555,977 votes for, 166,391 votes against, and 24,645 abstentions, and no broker non-votes reported.
How did Nurix Therapeutics’ stockholders vote on executive compensation in 2026?
Stockholders approved the compensation of Nurix’s named executive officers on a non-binding advisory basis. There were 72,458,920 votes for, 6,895,394 votes against, 573,204 abstentions, and 3,819,495 broker non-votes on this say-on-pay proposal.
How many votes did each Nurix Therapeutics director nominee receive in 2026?
Arthur T. Sands received 63,592,948 votes for and 16,334,570 withheld; Roger Dansey received 79,607,489 for and 320,029 withheld; Paul M. Silva received 59,298,612 for and 20,628,906 withheld, with 3,819,495 broker non-votes for each nominee.
AI-generated analysis. How Rhea-AI works. Not financial advice.
